Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

Dr Manu Vatish and Dr Sofia Cerdeira from the Nuffield Department of Women's and Reproductive Health have won a prestigious global award, that recognises teams that collaborate across disciplines and transform healthcare delivery and ultimately patient lives.

The annual UNIVANTS of Healthcare Excellence Award was given to credit the working partnership between Roche Diagnostics, Oxford University Hospitals NHS Foundation Trust and Oxford Academic Health Science Network. Their joint expertise resulted in a new test which predicts with much greater accuracy, whether a pregnant woman will develop Pre-eclampsia (PE) within the following seven days.

Pre- eclampsia is a hypertensive disorder of pregnancy, affecting 4-8% of women globally, causing major maternal and fetal morbidity. Roughly half of patients who are admitted to the hospital at risk of PE don’t end up suffering from the condition. Significant resources are used trying to identify PE mothers by measuring blood pressure and proteinuria. This is sub-optimal because these clinical signs have poor diagnostic accuracy, which means clinicians rely on clinical instinct.

“If you don’t have a firm diagnosis, you either incorrectly send someone with Pre-eclampsia home or incorrectly admit someone who doesn’t have Pre-eclampsia,” Vatish said. “Those are both bad outcomes for the professionals involved in their care.” 

Dr Manu Vatish, Dr Sofia Cerdeira and Dr Tim James (Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust) worked extensively around the potential use of laboratory tests that could offer clinicians reassurance of their PE diagnosis while avoiding hospitalization of patients who won’t develop the condition. They found significant opportunity in two angiogenic biomarkers: Placental Growth Factor (PlGF), and its receptor, Soluble Flt-1. These biomarkers showed a very powerful negative predictive value, meaning they were a reliable indicator of patients who were not likely to develop PE.

The test was developed by Roche Diagnostics and a clinical trial was run at the John Radcliffe Hospital (Oxford University Hospitals NHS Foundation Trust). Following improved patient outcomes, the Oxford Academic Health Science Network launched the test to other maternity units across the UK. It has been well-received by patients, who are often unnecessarily frightened when PE is explained to them during prenatal visits. Hospitalization can be a frustrating experience for patients who ultimately have their baby without issue.

This high profile award attracted 300 applications from 97 countries. It is a fantastic acknowledgment of how shared expertise across disciplines, including the core laboratory, can reshape care pathways and ultimately achieve better outcomes for patients, clinicians, payers and entire health systems. 


Latest news

Revolutionary AI Technology Reveals New Insights into Placental Health

A groundbreaking study, published in Nature Communications, unveils HAPPY - a pioneering tool that uses AI to revolutionise the analysis of placental health. Developed by an international team of researchers, HAPPY represents a significant leap forward in helping to understand the vital role of the placenta in maternal and fetal health.

NDWRH Winners at the Vice-Chancellor’s Awards

Lesa Levett has emerged victorious at yesterday’s VC Awards ceremony. Lesa was honoured with the prestigious "Enhancing Oxford’s Professional Services Award" in recognition of her remarkable contributions towards driving positive change within our department and her support in other departments within MSD.

Exploring the Role of Extracellular Vesicles in Fetal-Maternal Communication and Reproductive Disorders

In women’s and reproductive health, there is a growing body of work suggesting that extracellular vesicles have a critical role in communications between the fetus and mother, and also between the reproductive organs and the rest of the body. This is believed to be relevant to a range of pathological conditions, including complications in pregnancy such as preeclampsia, endometriosis, and infertility.

Study challenges conventional understanding of household air pollution's impact on fetal growth

In a ground-breaking study published today in Lancet Global Health, researchers present findings challenging conventional wisdom regarding the impact of household air pollution on fetal growth. The study, conducted in 3200 households across resource-poor settings in Guatemala, India, Rwanda, and Peru, focused on assessing the effects of reducing personal exposures to household air pollution on fetal growth in a randomized controlled trial.

Upcoming OxTalks

Our Research Groups